Planned/ongoing randomised controlled trials comparing SBRT versus surgery
| US POSTLIV trial (NCT01753414) | US STABLE-MATES trial (NCT02468024) | US Trial Mayo Clinic (NCT01622621) | UK SABRTooth trial (NCT02629458) | |
| Surgical study arm | Complete resection and lymph node dissection | SLR | SLR | Complete resection |
| SBRT study arm | 55 Gy in five fractions | 54 Gy in three fractions | 54 Gy in three fractions | Various dose/fraction schedules |
| Eligibility | Lobectomy or pneumonectomy, tumour ≤3 cm | “High operative risk” tumour ≤4 cm | “High operative risk” peripheral tumour ≤5 cm | “High operative risk” peripheral tumour ≤5 cm |
| Primary end-point | 2 year loco-regional control | 3 year OS | 2 year OS | Average recruitment 3 patients per month |
| Secondary end-points | Time to local/distant failure, DFS, OS | Toxicity, progression-free survival | Toxicity, progression-free survival | |
| Target recruitment | 76 patients | 258 patients | 96 patients | 54 patients |
SBRT: stereotactic body radiotherapy; SLR: sublobar resection; OS: overall survival; DFS: disease-free survival.